Akhil Farma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 4.19 M
- Company Age 34 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.80 M
- Revenue Growth 1009.62%
- Profit Growth 1477.70%
- Ebitda -148.92%
- Net Worth 36.96%
- Total Assets 36.97%
About Akhil Farma
Akhil Farma Limited (AFL) is a Public Limited Indian Non-Government Company incorporated in India on 09 March 1990 and has a history of 34 years and 11 months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.19 M.
The company currently has active open charges totaling ₹0.80 M.
Meera Chandavarkar, Chandrayani Nayak, and Anil Nadkarni serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397MH1990PLC055739
-
Company No.
055739
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
09 Mar 1990
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Akhil Farma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meera Chandavarkar
|
Director | 01-Apr-2015 | Current |
|
Chandrayani Nayak
|
Whole-Time Director | 01-Dec-2001 | Current |
|
Anil Nadkarni
|
Whole-Time Director | 14-Jan-2000 | Current |
Financial Performance of Akhil Farma.
Akhil Farma Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 1009.62% increase. The company also saw a substantial improvement in profitability, with a 1477.7% increase in profit. The company's net worth Soared by an impressive increase of 36.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Akhil Farma?
In 2021, Akhil Farma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Dss Out Sourcing Solutions Private LimitedMeera Chandavarkar is a mutual person
-
Kismet Exports And Investments P Ltd
Anil Nadkarni is a mutual person
Charges (Loans)
₹0.80 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Mar 1987 | Canara Bank | ₹0.80 M | Open |
How Many Employees Work at Akhil Farma?
Unlock and access historical data on people associated with Akhil Farma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Akhil Farma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Akhil Farma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
